Currently Skimming:
3 The Global Burden of Drug-Resistant TB
3 The Global Burden of Drug-Resistant TB
Pages 37-48
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 37... ...
• any countries with high levels of MDR TB could benefit from inter M national assistance to bridge the gap between current and needed capabilities. • gap between global notification of TB each year and estimated A incidence indicates that many people, including people with MDR TB, are not being diagnosed and treated by current approaches.
|
From page 38... ...
report on TB control for more information on global estimates of MDR TB. 2 This section is based on slides prepared for the workshop by Matteo Zignol, STOP TB Partnership, WHO, and presented by Salmaan Keshavjee, Assistant Professor, Harvard Medical School.
|
From page 39... ...
. In some cases, low success rates are due to a failure TABLE 3-1 Estimated Versus Reported MDR TB Cases in 2009 WHO Region Estimated Reported Ratio (%)
|
From page 40... ...
The overall rate of MDR TB in China among all TB cases ranges from 3.5 to 23.3 percent, depending on the province. China has embarked on a Global Fund pilot project to control MDR TB that incorporates enhanced service system and management mechanisms.
|
From page 41... ...
The prevention plan includes consolidation and enhancement of the strategy for DOTS implementation, increased accessibility and equalization of general TB control services, the production of quality-assured anti-TB drugs, standardized use and management of the drugs, and reinforced infection control measures. The control plan includes guaranteeing complementary government funding of the Global Fund project and further exploring and expanding the Gates MDR TB project.
|
From page 42... ...
Working with the government, Partners In Health purchased the necessary drugs and mobilized community health workers (CHWs) to deliver care, demonstrating that community-based delivery of MDR TB treatment is feasible in resource-limited settings.
|
From page 43... ...
Inadequate Diagnostic Capacity To diagnose MDR TB, rapid culture testing and DST are essential, Keshavjee stressed. Today, liquid bacterial culture can provide results in about 2 weeks, while molecular tests can provide results in 2 hours to 2 days.
|
From page 44... ...
monitor and evaluate the use of second-line drugs in approved projects, and (3) promote technical assistance for MDR TB programs in keeping with WHO guidelines.
|
From page 45... ...
The standard 18- to 24-month treatment course for MDR TB, using drugs procured through the GLC, costs between $4,400 and $9,000 per patient (MSF and IUATLD, 2011)
|
From page 46... ...
Inadequate International Assistance Many countries need help to bridge the gap between current capabilities and what is needed, yet international technical assistance is inadequate, Keshavjee emphasized. Successful regional MDR TB treatment programs have shown what can be done with on-site long-term technical assistance and, where necessary, on-site implementation teams.
|
From page 47... ...
A comprehensive framework would also include vulner able populations. • On-site long-term technical assistance and on-site implementation teams from within a given country or drawn from regional and international expertise can improve MDR TB treatment programs.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.